Consequently, this meta-analysis was performed for identifying its precise role in forecasting melanoma prognosis.<h4>Methods</h4>We searched PubMed, Web of Science, Embase and Cochrane Library till 25 January 2025, and computed combined hazard ratios (HRs) and 95% confidence intervals (CIs) for estimating CRP's effect on forecasting overall survival (OS) and progression-free survival (PFS) of melanoma.<h4>Results</h4>Nineteen studies consisting of 4634 cases were enrolled into the present work. The gene discussed is CRP; the disease is melanoma.